These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35159224)

  • 1. Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy.
    Obradovic DM; Büttner P; Rommel KP; Blazek S; Loncar G; von Haehling S; von Roeder M; Lücke C; Gutberlet M; Thiele H; Lurz P; Besler C
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
    Lichtenauer M; Jirak P; Wernly B; Paar V; Rohm I; Jung C; Schernthaner C; Kraus J; Motloch LJ; Yilmaz A; Hoppe UC; Christian Schulze P; Kretzschmar D; Pistulli R
    Eur J Intern Med; 2017 Oct; 44():31-38. PubMed ID: 28579310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of plasma TSG-6 with cardiac function, myocardial fibrosis, and prognosis in dilated cardiomyopathy patients with heart failure.
    Xu L; Zhang Y; Kuang Y; Fang H; Ma Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):689-696. PubMed ID: 34382584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study.
    Li F; Xu M; Fu M; Cui X; Lian Z; Xin H; Zhou J; Ge J
    BMC Cardiovasc Disord; 2021 Aug; 21(1):396. PubMed ID: 34404341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy.
    Weinmann K; Werner J; Koenig W; Rottbauer W; Walcher D; Keßler M
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31731547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ST2 and myocardial fibrosis in 3T cardiac magnetic resonance.
    Quick S; Waessnig NK; Kandler N; Poitz DM; Schoen S; Ibrahim K; Strasser RH; Speiser U
    Scand Cardiovasc J; 2015; 49(6):361-6. PubMed ID: 26287645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multislice spiral computed tomography of the heart in dilated cardiomyopathy: possibilities in the verification of myocarditis (in comparison with myocardial biopsy) and in the evaluation of prognosis].
    Alieva IN; Blagova OV; Gagarina NV; Nedostup AV; Kogan EA; Sedov VP; Kadochnikova VV; Donnikov AE; Zaidenov VA; Kupriyanova AG; Ternovoy SK
    Ter Arkh; 2017; 89(12):15-27. PubMed ID: 29411756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.
    Stojkovic S; Kaider A; Koller L; Brekalo M; Wojta J; Diedrich A; Demyanets S; Pezawas T
    J Cell Mol Med; 2018 Apr; 22(4):2422-2429. PubMed ID: 29397580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study.
    Bahuleyan CG; Alummoottil GK; Abdullakutty J; Lordson AJ; Babu S; Krishnakumar VV; Pillai AM; Abraham G; Dilip MN
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S79-S84. PubMed ID: 30122243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart Failure.
    Muksinova MD; Narusov OY; Sychev AV; Sharf TV; Masenko VP; Tereshchenko SN; Skvortsov AA
    Kardiologiia; 2023 Dec; 63(12):87-92. PubMed ID: 38156496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome.
    Park S; Kim IC; Kim H; Cho YK; Lee CH; Hur SH
    Heart Vessels; 2022 Feb; 37(2):173-183. PubMed ID: 34341876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy.
    Leyva F; Taylor RJ; Foley PW; Umar F; Mulligan LJ; Patel K; Stegemann B; Haddad T; Smith RE; Prasad SK
    J Am Coll Cardiol; 2012 Oct; 60(17):1659-67. PubMed ID: 23021326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure.
    Bai J; Han L; Liu H
    Ann Palliat Med; 2020 Jul; 9(4):1976-1989. PubMed ID: 32762223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
    Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endomyocardial biopsy-confirmed myocarditis and inflammatory cardiomyopathy: clinical profile and prognosis.
    Domínguez F; Cobas Paz R; Salas Antón C; Colomés Iess M; Oteo-Domínguez JF; Escobar-López L; de Frutos F; Cobo-Marcos M; González-López E; Hernández-Pérez FJ; Mitroi C; Briceño A; Rivas-Lasarte M; Gómez-Bueno M; García-Pavía P; Segovia-Cubero J
    Rev Esp Cardiol (Engl Ed); 2022 Nov; 75(11):874-882. PubMed ID: 35523665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.
    Krejci J; Hude P; Poloczkova H; Zampachova V; Stepanova R; Freiberger T; Nemcova E; Spinarova L
    Heart Vessels; 2016 Mar; 31(3):416-26. PubMed ID: 25539624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography.
    Leong DP; Chakrabarty A; Shipp N; Molaee P; Madsen PL; Joerg L; Sullivan T; Worthley SG; De Pasquale CG; Sanders P; Selvanayagam JB
    Eur Heart J; 2012 Mar; 33(5):640-8. PubMed ID: 22048681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitral annuloplasty in patients with ischemic versus dilated cardiomyopathy.
    Szalay ZA; Civelek A; Hohe S; Brunner-LaRocca HP; Klövekorn WP; Knez I; Vogt PR; Bauer EP
    Eur J Cardiothorac Surg; 2003 Apr; 23(4):567-72. PubMed ID: 12694777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.